Late treatment study
et al., medRxiv, doi:10.1101/2020.05.21.20109207 (Preprint)
Hydroxych loroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study
Retrospective study of late stage use on 2,512 hospitalized patients showing no significant differences in associated mortality for patients receiving any HC Q during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), HC Q alone (HR, 1.02 [95% CI, 0.83-1.27]), or HC Q+AZ (HR, 0.98 [95% CI, 0.75-1.28]). Misclassification is possible due to manual abstraction of EHR data. They observed a change in the prescribing patterns of HC Q during the study timeframe. Confounding by indication.
Please send us corrections, updates, or comments: